Please type a plus sign (+) inside the sox	1

PTO/SB/08A (08-00) use through 10/31/2002, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE office on the office of the o Under the Paperwork Reduction Act of 1995, no persons are required to respond to
Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use	as	many	sneets	as	necessary	
				_		-

of

ORNE C	omplet if Known	
Application Number	10/001,407	Ξ
Filing Date	October 22, 2001	₹
First Named Inventor	YANG et al.	7
Group Art Unit	In Be Assigned 1648	'n
Examiner Name	To Be Assigned PARICIN	Z
Attorney Docket Number	GP117-03.UT	П

			U.S. PATENT DOC	UMENTS		2
Cite No.¹	U.S. Pater Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7007
						
				_		
				 -		
				 		
			· · · ·			
				+		
						
				+		
		Cite		Cite U.S. Patent Document Name of Patentee or Applicant	Cite Name of Patentee or Applicant Cited Document	U.S. Patent Document Cite No. 1 Number Kind Code ² Name of Patentee or Applicant of Cited Document Octed Document No. 1 Number No. 1 Number No. 2


				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No.1	Office ³	Foreign Patent Docu Number ⁴	iment Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Ţ8
NC			0125466	A1	Oxford Biomedica (UK) Limited	04-12-2001		
NC			0162965	A2	Oxford Biomedica (UK) Limited	08-30-2001		
								<u> </u>
		 						
		.						

* An English language abstract is included. ** An English language abstract and English language claims are included.

Examiner Signature	Date Considered 08/10/0~

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-00) for use through 10/31/2002. OMB 0651-0031 fx Office: U.S. DEPARTMENT OF COMMERCE U. S. Patent and Trad

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/001,407 October 22, 2001 **Filing Date First Named Inventor** YANG tal. **Group Art Unit** 1648 Parkin, J. **Examiner Name GP117-03.UT**

FEB 2 0 2003

Sheet 1 of

(use as many sheets as necessary) **Attorney Docket Number**

1		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	-
Examine Initials	r Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
7		BERKHOUT et al., "Secondary Structure of the HIV-2 Leader RNA Comprising the tRNA-Primer Binding Site", Nucleic Acids Res., Mar. 1993, 21(5):1171-1178	
1		BERKHOUT et al., DATABASE GSN, Online!, Jun. 1993, retrieved from EBI Database accession no. X72325	
		BUSH et al., "Detection of Human immunodeficiency Virus Type 1 RNA in Plasma Samples from High-Risk Pediatric Patients by Using the Self-Sustained Sequence Replication Reaction", J Clin Microbiol., Feb. 1992, 30(2):281-286	
		DE BAAR et al., "Design and Evaluation of a Human immunodeficiency Virus Type 1 RNA Assay Using Nucleic Acid Sequence-Based Amplification Technology Able to Quantify Both Group M and O Viruses by Using the Long Terminal Repeat as Target" J Clin Microbiol., Jun. 1999, 37(6):1813-1818.	
		EIKEN CHEM CO LTD., DATABASE GSN, Online!, July 1998, retrieved from EBI Database accession no. AAV19509	
		KRAISELBURD, DATABASE GSN, Onlinel, Jun. 1996, retrieved from EBI Database accession no. AAT06604	
		PIENIAZEK et al., "identification of Mixed HIV-1/HIV-2 infections in Brazil by Polymerase Chain Reaction", AIDS, Nov. 1991, 5(11):1293-1299	
4		VAN GEMEN et al., "The One-Tube Quantitative HIV-1 RNA NASBA: Precision, Accuracy, and Application", PCR Methods Appl., Feb. 1995, 4(4):S177-S184	
		RE FECH C	
		RECEIVED FEB 2 4 2003 FECH CENTER 1600/290	
		VEL 2003	
		2900	,

	·		
Examiner		Date	, ,
Signature		Considered	03/10/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial lyreference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

_	-
ח	Γ
0	
	Π
	-

Please type a plus sign (+) inside this box

Substitute for form 1449B/PTO

Sheet

PTO/SB/08B (08-00) Approved for use through 10/31/2002. OMB 0651-0031 S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number

Under the Peperwork Reduction Act of 1995, no persons are required to respond to

ENT . THA Complet if Kn wn **Application Number** 10/001.407

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Group Art Unit **Examiner Name**

Filing Date

Oct ber 22, 2001 YANG et al. First Named Inventor To B Assigned /648 To Be Assigned PARKETON

Attorney Docket Number **GP117-03.UT**

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials publisher, city and/or country where published. ABRAVAYA et al., "Performance of a Multiplex Qualitative PCR LCx Assay for Detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M Subtypes, Group O, and HIV-2", J. Clin. Microbiol., Feb. NC 2000, 38(2):716-23, American Society for Microbiology, US DIAMOND et al., "Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA", J. Clin. Microbiol., March 1998, 36(3):809-811, American Society for Microbiology, US REEVES et al., "Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo", J. Virol., Sept. 1999, 73(9):7795-804, American Society for Microbiology, US WALTHER-JALLOW et al., "High Concordance between Polymerase Chain Reaction and Antibody Testing of Specimens from Individuals Dually Infected with HIV Types 1 and 2 in Guinea-Bissau, West Africa", AIDS Res. Hum. Retroviruses, July 1999, 15(11):957-62, Mary Ann Liebert Incorporated, US

Examiner Signature	7	Date Considered 03 / co / 04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NC-Reference not considered. IDS fail t comply with 37 CRR 1.98 Cg)C2)

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

Approved for use through 10/31/2002. OMB 0851-0031

Exercise through 10/31/2002. OMB 0851-0031

Approved for use through 1 Under the Paperwork Reduction Act of 1995, no persons are E CAL TI

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

ADEMARY CO	omplete if Known
Application Number	10/001,407
Filing Date	October 22, 2001
First Named Inventor	YANG et al.
Group Art Unit	To Be Assigned 1648
Examiner Name	To Bo Assigned PARKEN
Attorney Docket Number	GP117-03.UT

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Mumber	ment Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
NE		4868105	A	Urdea et al.	09-19-1989	
		4965188	·A	Mullis et al.	11-23-1990	
$\neg \Box$		5008182	Α	Sninsky et al.	04-16-1991	
		5066782	Ā	Montagnier et al.	11-19-1991	
		5124246	. A	Urdea et al.	06-23-1992	
		5130238	. A	Malek et al.	07-14-1992	
$\neg \neg$		5176995	·A	Sninsky et al.	01-05-1993	
		5223423	- A	Franchini et al.	06-29-1993	
		5283174	.Α	Arnold, Jr. et al.	02-01-1994	
		5310651	. A	Alizon et al.	05-10-1994	
		5399491	·A	Kacian et al.	03-21-1995	
		5437990	·Α	Burg et al.	08-01-1995	
1 [5455166	·A	Walker	10-03-1995	
		5470572	Α	Kraiselburd	11-28-1995	
		5472840	Α	Stefano	12-05-1995	·
		5545726	·A	Alizon et al.	08-13-1996	
		5554516	.A	Kacian et al.	09-10-1996	
		5591578	Α	Meade et al.	01-07-1997	
		5639604	·A	Arnold, Jr. et al.	06-17-1997	
1		5656207	ſA	Woodhead et al.	08-12-1997	

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	I Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6
NC		EP	0239425	A1	Institut Pasteur	09-30-1997		*
1		EP	0403333	B1	Institut Pasteur et al.	12-19-1990		**
\neg		EP	0404625	B1	Institut Pasteur et al.	12-27-1990		##
		EP	0525882	A1	Akzo N.V.	02-03-1993		
		EP	0655501	A1	Qlagen GmbH et al.	05-31-1995		
		EP	0750041	A2	Institut Pasteur	12-27-1996		*
		EP	0806484	A2	Institut Pasteur et el.	11-12-1997		•
		EP	0887427	A2	Ortho-Clinical Diagnostics, Inc.	12-30-1998		
		EP	1026263	A2	Ortho-Clinical Diagnostics, Inc.	08-09-2000		
₩		wo	8801302	A1	Siska Diagnostics, Inc.	02-25-1988		

^{*} An English language abstract is included. ** An English language abstract and English language claims are included.

Examiner Signature	Date Considered 03/10/04

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NC-References met considered. IDS Beicht comply with 37 CFR 1.98(9)(2).



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside the x

FEB 1 2 2007 3

Approved to see through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no person are required to respond Compl te if Known Substitute for form 1449A/PTO 10/001,407 **Application Number** INFORMATION DISCLOSURE October 22, 2001 **Filing Date** STATEMENT BY APPLICANT YANG et al. First Named Inventor To Be Assigned Group Art Unit (use as many sheets as necessary) To Be Assigned PARKETA **Examiner Name GP117-03.UT** Attorney Docket Number of Sheet

т		II C Potent	Document I	U.S. PATENT DOCI		Pages, Columns, Lines,
Examiner nitials*	Cite No. ¹	U.S. Patent Document Kind Code² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Whare Relevant Passages or Relevant Figures Appear
NC		565873	7 -A	Nelson et al.	08-19-1997	
1		568863	7 A	Moncany et al.	11-18-1997	
$\neg \neg$		571238	5 'A	McDonough et al.	01-27-1998	
$\neg \neg$		5770369	9 'A	Meade et al.	06-23-1998	
		578620	B -A	Clark et al.	07-28-1998	
		582793	5 A	Rossi et al.	10-27-1998	
		584048	ВА	Hogan	11-24-1998	
		5840873	3 A	Nelson et al.	11-24-1998	
		584365	4 A	Heisler et al.	12-01-1998	
		584366	9 ·A	Kaiser et al.	12-01-1998	
$\neg \neg$		585608	В А	McDonough et al.	01-05-1999	
$\neg \sqcap$		596266	5 A	Kroeger et al.	10-05-1999	
$\neg \sqcap$		5976814	4 .A	Bard et al.	11-02-1999	
\Box		599817	2 A	Haynes et al.	12-07-1999	
		600155	В А	Backus et al.	12-14-1999	
		602012	3 A	Sonigo et al.	02-01-2000	
4		609632	1 'A	Girardeau et al.	08-01-2000	
-						
						

				FORI	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Foreign Patent Document Kind Code ⁵			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		Office ³	Number ⁴	(if known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	1e
NC		wol	8810315	A1	Siska Diagnostics, Inc.	12-29-1988		
1		wo	9322461	A1	Gen-Probe Incorporated	11-11-1993		
		wo	9403472	A1	Gen-Probe Incorporated	02-17-1994		
\vdash		wol	9414967	A2	Institut National De La Recherché Agronomique	07-07-1994		•
		wo	9503430	A1	Gen-Probe incorporated	02-02-1995		
		wo	9532305	A1	Dako A/S	11-30-1995		
		wo	9850583	A1	Gen-Probe Incorporated	11-12-1998		
		WO	9855640	A1	Oxford Biomedica (UK) Limited	12-10-1998		
		wo	0001850	A2	Gen-Probe Incorporated	01-13-2000		
*		wo	0125419	A1	Cyto-Genix, Inc.	04-12-2001		

* An English language abstract is included. ** An English language abstract and English language claims are included.

Examiner Signature	Date Considered 03/10/04
-----------------------	--------------------------

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

NC - Welczenson March Commissioner for Patents, Washington, DC 20231.

NC-reference mot consideral. EDS faile to comply with

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.